Weight-loss decision guide
Peptides for Weight Loss: Approved Options, Compounded Claims, and Clinic Checks
Start with the product's regulatory status, then check the clinician, pharmacy, follow-up plan, and price.
Updated August 21, 2026
Some peptide-based medicines have FDA approval for chronic weight management, including semaglutide sold as Wegovy and tirzepatide sold as Zepbound. A compounded product, an investigational compound such as retatrutide, or a peptide discussed by an FDA advisory committee does not share that approval status.
Four different claims that often sound alike
The ingredient name alone cannot tell you what a clinic is offering. Ask for the product name, indication, prescriber, dispensing pharmacy, and FDA status.
| Claim type | Examples | What the record establishes | What to verify |
|---|---|---|---|
| FDA approved Named medicine | Wegovy (semaglutide); Zepbound (tirzepatide) | FDA approved these named products for chronic weight management in specified patient groups. Approval includes a reviewed label, manufacturing controls, and postmarket requirements. | Confirm the exact brand or product, indication, prescriber, pharmacy, and whether the clinician says the approved label fits your situation. |
| Compounded Patient-specific preparation | Products described as compounded semaglutide or tirzepatide | FDA does not approve compounded drugs or review them before marketing for safety, effectiveness, or quality. Federal exemptions carry patient-specific and copy restrictions. | Ask why an available approved product cannot meet the patient's medical need, which licensed pharmacy will dispense it, and what appears on the label. |
| Investigational Clinical research | Retatrutide | A trial registration records research. It does not establish FDA approval, a retail product, a retail price, or clinic availability. | Check ClinicalTrials.gov and FDA sources. Treat a consumer sales claim as a separate claim that needs proof. |
| Advisory review Nonbinding recommendation | MOTS-c, reviewed in an obesity and osteoporosis context | The July 2026 PCAC recommendation was one step in a federal compounding-policy process. It was not FDA drug approval or proof of effectiveness. | Read the dated committee record and the peptide status tracker. Do not substitute an advisory vote for a product label or clinical evidence. |
FDA approval follows the named product and indication
FDA approved Zepbound, which contains tirzepatide, for chronic weight management in specified adults. FDA's March 2026 Wegovy announcement describes an approved semaglutide product for weight loss and long-term weight maintenance in specified adults.
A clinic's use of the words semaglutide, tirzepatide, or GLP-1 does not identify the product. The offer could involve an FDA-approved branded medicine, a compounded preparation, a clinic membership, or a consultation without medicine included.
For the booking side of the decision, use the GLP-1 clinic checklist and the separate semaglutide clinic payment checks.
How to read a compounded GLP-1 claim
FDA says compounded GLP-1 drugs are not FDA approved. The agency does not review compounded drugs before marketing for safety, effectiveness, or quality. FDA also warns about fraudulent labels, salt forms of semaglutide, dosing errors, and products marketed with claims that overstate what regulators reviewed.
As of May 31, 2026, FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. Those reports do not prove causation or calculate incidence. FDA notes that reporting from state-licensed pharmacies is not complete.
FDA's compounder policy clarification explains patient-specific prescription and copy restrictions under sections 503A and 503B. Ask the clinic to explain the exact medical need, product, pharmacy, and label instead of relying on a shortage-era sales script.
Retatrutide trial claims and MOTS-c advisory claims
ClinicalTrials.gov lists the TRIUMPH-1 retatrutide study. A trial record documents research; it does not create an approved retail product. FDA's current unapproved GLP-1 page states that retatrutide has not been found safe and effective for any condition and cannot be used in compounding under federal law.
Use the focused guides for retatrutide access claims, retatrutide safety evidence, and retatrutide price claims.
FDA's July 2026 PCAC record lists MOTS-c in an obesity and osteoporosis review context. Advisory committees make nonbinding recommendations. Read the MOTS-c status page before treating a marketing claim as an FDA decision.
Seven questions to ask before paying a clinic
- Who will evaluate me? Get the clinician's full name, professional license, state, and role in prescribing and follow-up.
- What exact product are you discussing? Ask for the active ingredient, brand or compounded status, indication, and FDA status.
- Which pharmacy will dispense it? Get the pharmacy's legal name and state, then verify its license independently.
- Why is a compounded preparation being considered? Ask why an available FDA-approved product cannot meet the patient's documented medical need.
- What follow-up does the quoted price include? Separate the consultation, laboratory work, medicine, supplies, and follow-up visits.
- What happens if the clinician decides against treatment? Read refund, cancellation, renewal, and unused-membership terms before payment.
- Where can I verify each claim? Use FDA records, state license databases, the dispensing label, and the clinic's written terms.
FPC's verification methodology explains what the directory checks. The clinic finder helps you compare licensed-care paths; a listing does not prove that a clinic offers or recommends a named medicine.
Questions people ask about weight-loss peptides
Which peptide medicines are FDA approved for weight loss?
Semaglutide sold as Wegovy and tirzepatide sold as Zepbound have FDA-approved chronic-weight-management indications for specified patients. Approval belongs to the named product and indication, not to every product marketed with the active ingredient's name.
Are compounded semaglutide and tirzepatide FDA approved?
No. FDA does not approve compounded drugs or review them before marketing for safety, effectiveness, or quality. Federal compounding exemptions have conditions, including patient-specific and copy restrictions.
Is retatrutide FDA approved for weight loss?
No. Retatrutide remains investigational. A clinical-trial record or sponsor announcement does not establish FDA approval or retail availability.
Did the FDA advisory committee approve MOTS-c for obesity?
No. The committee reviewed MOTS-c in an obesity and osteoporosis context and made a nonbinding recommendation in July 2026. An advisory recommendation is not FDA drug approval.
How can I check a weight-loss clinic before paying?
Ask for the clinician's license, the exact product and FDA status, the dispensing pharmacy, the reason for any compounded prescription, the follow-up plan, the full price, and the refund or cancellation terms. Verify the answers independently.
Primary sources
- FDA. Zepbound approval for chronic weight management.
- FDA. Wegovy higher-dose approval announcement.
- FDA. Concerns with unapproved GLP-1 drugs used for weight loss.
- FDA. Policies for compounders after national GLP-1 supply stabilization.
- ClinicalTrials.gov. TRIUMPH-1 retatrutide study record.
- FDA. July 23-24, 2026 PCAC meeting record.